异源人/大鼠HER2特异性外泌体靶向T细胞疫苗可激发强效体液和CTL应答并增强对双转基因HLA-A2/HER2小鼠HER2耐受的规避
研究构建表达人HER2与大鼠neu融合蛋白的腺病毒载体,并制备异源人/大鼠HER2特异性外泌体靶向T细胞疫苗HuRt-TEXO。在双转基因HLA-A2/HER2小鼠中,该疫苗较同源HER2-TEXO疫苗诱导更强的HER2特异性抗体(约70 µg/ml vs 约40 µg/ml)和CD8+ T细胞应答(清除90% vs 53%靶细胞),并能抑制早期4T1HER2乳腺癌肺转移或皮下生长、完全保护HLA-A2/HER2小鼠抵抗BL6-10A2/HER2黑色素瘤生长。
要点
- HuRt-TEXO诱导的HER2特异性抗体约70 µg/ml,高于同源HER2-TEXO的约40 µg/ml。
- HuRt-TEXO激发的CD8+ T细胞清除90% HER2特异性靶细胞,同源疫苗仅清除53%。
- HuRt-TEXO可抑制早期4T1HER2乳腺癌肺转移或皮下生长,并完全保护HLA-A2/HER2小鼠抵抗BL6-10A2/HER2黑色素瘤生长。
核心结论
- 异源人/大鼠HER2特异性T细胞疫苗HuRt-TEXO可规避HER2耐受,可能为曲妥珠单抗耐药的HER2+乳腺肿瘤患者提供新的治疗选择。
研究设计与样本
- 研究构建表达NH2-HER21-407(Hu)与COOH-neu408-690(Rt)融合蛋白的腺病毒载体AdVHuRt,并利用摄取AdVHuRt转染树突状细胞释放外泌体的多克隆CD4+ T细胞制备异源人/大鼠HER2特异性外泌体靶向T细胞疫苗HuRt-TEXO。
- 在双转基因HLA-A2/HER2小鼠、BALB/c小鼠、athymic nude小鼠中评价HuRt-TEXO的免疫应答与抗肿瘤效果。
主要发现
- HuRt-TEXO疫苗诱导的HER2特异性抗体约70 µg/ml,高于同源HER2-TEXO疫苗诱导的约40 µg/ml。
- 经PE-H-2Kd/HER223-71四聚体检测,HuRt-TEXO激发的HER2特异性CD8+ T细胞清除90% HER2特异性靶细胞,而同源HER2-TEXO诱导的CD8+ T细胞仅清除53%靶细胞。
- HuRt-TEXO而非HER2-TEXO疫苗接种可抑制BALB/c小鼠中早期已建立的表达HER2的4T1HER2乳腺癌肺转移或皮下形式,并使双转基因HLA-A2/HER2小鼠完全免于表达HLA-A2/HER2的BL6-10A2/HER2黑色素瘤生长。
- HuRt-TEXO激发的HER2特异性CD8+ T细胞在体外对曲妥珠单抗耐药的表达HLA-A2/HER2的BT474/A2乳腺肿瘤细胞具有溶细胞作用,并在athymic nude小鼠中清除预先建立的BT474/A2肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DNA vaccines composed of heterologous human HER2 and rat neu sequences induce stronger antibody response and protective antitumor immunity than either HER2 or neu DNA vaccines in transgenic mice. We previously developed HER2-specific exosome-targeted T-cell vaccine HER2-TEXO capable of stimulating HER2-specific CD8+ T-cell responses, but only leading to partial protective immunity in double-transgenic HLA-A2/HER2 mice with self-immune tolerance to HER2. Here, we constructed an adenoviral vector AdVHuRt expressing HuRt fusion protein composed of NH2-HER21-407 (Hu) and COOH-neu408-690 (Rt) fragments, and developed a heterologous human/rat HER2-specific exosome-targeted T-cell vaccine HuRt-TEXO using polyclonal CD4+ T-cells uptaking exosomes released by AdVHuRt-transfected dendritic cells. We found that the HuRt-TEXO vaccine stimulates enhanced CD4+ T-cell responses leading to increased induction of HER2-specific antibody (∼70 µg/ml) compared to that (∼40 µg/ml) triggered by the homologous HER2-TEXO vaccine. By using PE-H-2Kd/HER223-71 tetramer, we determined that HuRt-TEXO stimulates stronger HER2-specific CD8+ T-cell responses eradicating 90% of HER2-specific target cells, while HER2-TEXO-induced CD8+ T-cell responses only eliminating 53% targets. Furthermore, HuRt-TEXO, but not HER2-TEXO vaccination, is capable of suppressing early stage-established HER2-expressing 4T1HER2 breast cancer in its lung metastasis or subcutaneous form in BALB/c mice, and of completely protecting transgenic HLA-A2/HER2 mice from growth of HLA-A2/HER2-expressing BL6-10A2/HER2 melanoma. HuRt-TEXO-stimulated HER2-specific CD8+ T-cells not only are cytolytic to trastuzumab-resistant HLA-A2/HER2-expressing BT474/A2 breast tumor cells in vitro but also eradicates pre-established BT474/A2 tumors in athymic nude mice. Therefore, our novel heterologous human/rat HER2-specific T-cell vaccine HuRt-TEXO, circumventing HER2 tolerance, may provide a new therapeutic alternative for patients with trastuzumab-resistant HER2+ breast tumor.
引用
- Xie Y, Wu J, Xu A, et al. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice. Vaccine. 2018. PMID: 29415817. doi:10.1016/j.vaccine.2018.01.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。